newsbreast cancerCDK4/6 inhibitors
Corneal Epithelial Changes Induced by CDK4/6 Inhibitors in HR+ Breast Cancer: Clinical Insights and Implications
By MedXY|Oct 14, 2026
CDK4/6 inhibitor therapy in hormone receptor-positive breast cancer is linked to increased corneal epithelial alterations, including punctate epitheliopathy and vortex keratopathy, independent of aromatase inhibitor effects or tear film dys